Robert Davey, PhD
Professor
Boston University Chobanian & Avedisian School of Medicine
Virology, Immunology & Microbiology

PhD, University of Adelaide
BSc, University of Adelaide



Dr. Robert Davey, PhD is a currently a Professor of Microbiology at the Chobanian and Avedisian School of Medicine. Dr. Davey received his doctorate in Microbiology and Immunology at the University of Adelaide in Australia. He continued his training as a Postdoctoral Fellow at the Howard Hughes Medical Institute and then at the Division of Hematology, both with Dr. James Cunningham at Brigham and Women's Hospital and Harvard Medical School.

Dr. Davey's first academic appointment was as an Instructor in Medicine at Harvard. He then held an Assistant Professor position which he got promoted to Adjunct Associate Professor at the Department of Microbiology and Immunology at the University of Texas Medical Branch.

Dr. Davey was also a Ewing Halsell Scholar and Scientist at the Department of Virology and Immunology at the Texas Biomedical Research Institute. As a Scientist at the Texas Biomedical Research Institute, Dr. Davey's work was focused on identification of cellular factors important for establishing infection by filovirus and bunyaviruses. His work has culminated in a deeper understanding of the entry and cell signaling pathways that are used by these viruses to penetrate the cell membrane and establish infection. His work with Ebolavirus has been published in the high-impact journals PLoS Pathogens, PNAS and a new article on host factor dependence in Science that was featured on the cover page. Dr. Davey’s group works collaboratively with a number of groups providing sophisticated molecular biology and cell biology techniques for the study of pathogenic viruses including Ebolavirus for which the lab mainly works. He has developed high throughput screening techniques for Ebolavirus. He also performs contract work testing drugs and compounds for ebolavirus infection inhibition. His team is well trained in ABSL4 procedures and have been working with Ebolavirus since 2006.

From 2015-2017, Dr. Davey held the role of Interim Chair in the Department of Virology and Immunology at the Texas Biomedical Research Institute. He is also Director of ABSL4 at the Texas Biomedical Research Institute.

Faculty
Boston University
National Emerging Infectious Disease Lab


Member
Boston University Chobanian & Avedisian School of Medicine
Evans Center for Interdisciplinary Biomedical Research


Graduate Faculty (Primary Mentor of Grad Students)
Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences




Optimizing Ridaifen-B analogs as potential therapeutics for Ebola viruses
09/20/2022 - 07/31/2027 (Subcontract PI)
University of Illinois NIH NIAID
1R01AI168362-01A1

National Emerging Infectious Diseases Laboratories Operations
07/08/2021 - 06/30/2026 (Key Person)
PI: Nancy J. Sullivan, ScD
NIH/National Institute of Allergy & Infectious Diseases
5UC7AI095321-10

Center for Antiviral Medicines & Pandemic Preparedness (CAMPP) - PROJECT 6
05/16/2022 - 04/30/2025 (Subcontract PI)
The Scripps Research Institute NIH NIAID
1U19AI171443-01

Midwest AViDD Center - CORE E
05/16/2022 - 04/30/2025 (Subcontract PI)
Regents of the University of Minnesota NIH NIAID
1U19AI171954-01

Evaluation of compounds from NU and IAM for Ebola virus treatment
11/15/2022 - 11/15/2024 (Subcontract PI)
Oita University Institute of Advanced Medicine, Inc Nagasaki University


Antiviral Lead Identification to Treat Filovirus Infections
08/12/2019 - 07/31/2024 (Subcontract PI)
Purdue University NIH NIAID
5R01AI128364-04

Perturbing virus replication with interfering peptides
04/25/2022 - 03/31/2024 (Subcontract PI)
Purdue University NIH NIAID
5R21AI166736-02

Assay development and execution of live virus testing in support of the Harvard-AbbVie Research Collaboration
03/01/2021 - 02/28/2024 (Subcontract PI)
President & Fellows of Harvard College on behalf of Harvard Medical School AbbVie


Small molecule inhibitors of Ebola virus polymerase function
02/01/2022 - 01/31/2024 (Subcontract PI)
Icahn School of Medicine at Mount Sinai NIH NIAID
7R01AI125453-06

Evaluation of SARS-COV-2 nuclease conjugates for treatment in the rodent model of SARS-COV-2 disease
07/01/2021 - 12/31/2023 (PI)
Massachusetts Institute of Technology


Showing 10 of 22 results. Show All Results


Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Xu D, Powell AE, Utz A, Sanyal M, Do J, Patten JJ, Moliva JI, Sullivan NJ, Davey RA, Kim PS. Design of universal Ebola virus vaccine candidates via immunofocusing. Proc Natl Acad Sci U S A. 2024 Feb 13; 121(7):e2316960121.View Related Profiles. PMID: 38319964; PMCID: PMC10873634; DOI: 10.1073/pnas.2316960121;
     
  2. Donahue CJ, Kesari A, Thakur N, Wang L, Hulsey-Stubbs S, Williams CG, Kirby CD, Leung DW, Aryal UK, Basler CF, LaCount DJ, Davey RA. A protein-proximity screen reveals Ebola virus co-opts the mRNA decapping complex through the scaffold protein EDC4. Res Sq. 2024 Feb 02. PMID: 38352529; DOI: 10.21203/rs.3.rs-3838220/v1;
     
  3. Bird GH, Patten JJ, Zavadoski W, Barucci N, Godes M, Moyer BM, Owen CD, DaSilva-Jardine P, Neuberg DS, Bowen RA, Davey RA, Walensky LD. A stapled lipopeptide platform for preventing and treating highly pathogenic viruses of pandemic potential. Nat Commun. 2024 Jan 04; 15(1):274. PMID: 38177138; PMCID: PMC10766962; DOI: 10.1038/s41467-023-44361-1;
     
  4. Xu D, Powell AE, Utz A, Sanyal M, Do J, Patten JJ, Moliva JI, Sullivan NJ, Davey RA, Kim PS. Design of universal Ebola virus vaccine candidates via immunofocusing. bioRxiv. 2023 Oct 17.View Related Profiles. PMID: 37904982; PMCID: PMC10614775; DOI: 10.1101/2023.10.14.562364;
     
  5. Aguilar-Briseño JA, Elliff JM, Patten JJ, Wilson LR, Davey RA, Bailey AL, Maury WJ. Effect of Interferon Gamma on Ebola Virus Infection of Primary Kupffer Cells and a Kupffer Cell Line. Viruses. 2023 Oct 11; 15(10). PMID: 37896854; PMCID: PMC10611415; DOI: 10.3390/v15102077;
     
  6. Wu C, Wagner ND, Moyle AB, Feng A, Sharma N, Stubbs SH, Donahue C, Davey RA, Gross ML, Leung DW, Amarasinghe GK. Disruption of Ebola NP0VP35 Inclusion Body-like Structures reduce Viral Infection. J Mol Biol. 2023 Oct 15; 435(20):168241. PMID: 37598728
     
  7. Wu C, Wagner N, Moyle AB, Feng A, Sharma N, Stubbs SH, Donahue C, Davey R, Gross ML, Leung DW, Amarasinghe GK. The Ebola NP0VP35 Complex Phase Separates into Inclusion Body-Like Structures. Microsc Microanal. 2023 Jul 22; 29(29 Suppl 1):941. PMID: 37613387
     
  8. Zou C, Yoon H, Park PMC, Patten JJ, Pellman J, Carreiro J, Tsai JM, Li YD, Roy Burman SS, Donovan KA, Gasser J, Sperling AS, Nowak RP, Fischer ES, Davey RA, Ebert BL, Slabicki M. The human E3 ligase RNF185 is a regulator of the SARS-CoV-2 envelope protein. iScience. 2023 May 19; 26(5):106601. PMID: 37095859; PMCID: PMC10082641; DOI: 10.1016/j.isci.2023.106601;
     
  9. Rayaprolu V, Fulton BO, Rafique A, Arturo E, Williams D, Hariharan C, Callaway H, Parvate A, Schendel SL, Parekh D, Hui S, Shaffer K, Pascal KE, Wloga E, Giordano S, Negron N, Ni M, Copin R, Atwal GS, Franklin M, Boytz RM, Donahue C, Davey R, Baum A, Kyratsous CA, Saphire EO. Structure of the Inmazeb cocktail and resistance to Ebola virus escape. Cell Host Microbe. 2023 Feb 08; 31(2):260-272.e7. PMID: 36708708; PMCID: PMC10375381; DOI: 10.1016/j.chom.2023.01.002;
     
  10. Boytz R, Seitz S, Gaudiano E, Patten JJ, Keiser PT, Connor JH, Sharpe AH, Davey RA. Inactivation of Ebola Virus and SARS-CoV-2 in Cell Culture Supernatants and Cell Pellets by Gamma Irradiation. Viruses. 2022 Dec 23; 15(1).View Related Profiles. PMID: 36680083; PMCID: PMC9866162; DOI: 10.3390/v15010043;
     
Showing 10 of 125 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 125 publications over 29 distinct years, with a maximum of 11 publications in 2021 and 2022

YearPublications
19831
19911
19922
19961
19972
19981
19991
20011
20041
20052
20068
20073
20084
20092
20104
20116
20126
20134
20147
20157
20165
20173
20188
20194
202010
202111
202211
20236
20243


Recent (within 3 months)

Novel Compound Protects Against Infection by Virus That Causes COVID-19, Preliminary Studies Show

ReachMD 1/8/2024

Novel Compound Shields Against COVID-19 in Preliminary Tests

MIrage News 1/6/2024

Older

Uncovering the first FDA-approved drug for Ebola virus infection

Drug Target Review 2/6/2023

Structure and function of the first FDA-approved treatment for Ebola virus discovered

News Medical 1/30/2023

Can COVID-19 Reboot Drug Repurposing?

Inside Precision Medicine 12/20/2022

Best of The Brink 2022: BU’s Most-Read Science and Research Stories

BU Today 12/13/2022

ONE YEAR LATER: LESSONS FROM THE PANDEMIC

BU Today 3/16/2021

In It Together 6/2/2020

WGBH 6/2/2020

BU Scientists Awarded $1.9 Million to Accelerate Coronavirus Research

BU Today 5/13/2020

Massachusetts Consortium Tests Thousands Of Existing Drugs Against Coronavirus

CBS Boston 5/13/2020

Decoding COVID-19

PBS Nova 5/13/2020

BU Labs, Researchers and Students Fight COVID-19

The Daily Free Press 4/29/2020

Episode 195: Does New England Have Enough COVID-19 Tests; The Fight To Save Yiddish

New England News Collaborative 4/23/2020

Will Antibody Testing Help Get People Back to Work?

PBS Newshour 4/21/2020

Needles In A Haystack: Could Existing Drugs Treat COVID-19?

WGBH 4/15/2020

Getting to Know the Enemy

WGBH 4/10/2020

BU NEIDL Scientists Can “See Enemy,” Making Headway on COVID-19 Research

Mirage News 4/7/2020

Coming: A New Appreciation For The Social Benefits Of Graduate Education

Forbes 4/6/2020

Get A Peek Inside The Search For COVID-19 DrugsL

Futurity 3/23/2020

Boston Researchers on the Frontline in the Battle Against Coronavirus

Boston 25 News 3/20/2020

Live Coronavirus Research Gets Underway at BU NEIDL

BU Today 2/19/2020

Ebola Treatment Massively Cuts Death Rate, But It’s No Cure

Futurity 8/16/2019

Malaria Drug Shows Promise For Treating Ebola

Futurity 11/30/2018

Old Drug, New Tricks

BU Today 11/19/2018

2015 San Antonio business journal: Outstanding medical researcher, Healthcare heroes awards
2005 UTMB Graduate school teaching award
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Marburg
Ebolavirus
ABSL4
Virology
Immunology
bunyaviruses
arenaviruses
Junin virus
Lassa Fever
Filoviruses
Contact for Mentoring:

620 Albany Street
Boston MA 02118
Google Map


Davey's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department